---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-022597"
form_type: "8-K"
ticker: "CCCC"
cik: "0001662579"
company_name: "C4 Therapeutics, Inc."
filed_at: "2023-06-20T23:59:59+00:00"
generated_at: "2026-06-13T21:23:30.980756+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# C4 Therapeutics appoints Leonard Reyno, M.D. as Chief Medical Officer effective July 10, 2023

## Summary
- Dr. Reyno receives $550K base salary, $200K sign-on bonus, and up to 40% performance bonus.
- Inducement option for 276,000 shares (25% vests year 1, rest quarterly over three years) plus 61,300 RSUs vesting over four years.
- Reyno brings ~30 years of oncology clinical experience; previously led Padcev early development, Herceptin and Taxotere FDA approvals.
- Stockholders elected three Class III directors, approved executive compensation, ratified KPMG as auditor, and approved officer liability limitation charter amendment.

## SEC filing metadata
- accession: 0001628280-23-022597
- form_type: 8-K
- ticker: CCCC
- cik: 0001662579
- company_name: C4 Therapeutics, Inc.
- filed_at: 2023-06-20T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662579/000162828023022597/0001628280-23-022597-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662579/000162828023022597/cccc-20230620.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-022597
- JSON: https://secwatch.observer/filing/0001628280-23-022597.json
- Plain text: https://secwatch.observer/filing/0001628280-23-022597.txt

## Key facts
- Executive change
  Leonard M.J. Reyno, M.D. was appointed as Chief Medical Officer at C4 Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Medical Officer
  source text: On June 20, 2023, C4 Therapeutics, Inc. (the “ Company ” or “ us ”), announced the appointment of Leonard M.J. Reyno, M.D. as its Chief Medical Officer, effective as of July 10, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662579/000162828023022597/0001628280-23-022597-index.htm
- Shareholder Votes
  C4 Therapeutics, Inc. shareholders approved Non-binding advisory vote to approve compensation of named executive officers at the 2023-06-15 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-06-15
  source text: The stockholders of the Company cast a non-binding, advisory vote to approve the compensation of the Company’s named executive officers.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662579/000162828023022597/0001628280-23-022597-index.htm
- Shareholder Votes
  C4 Therapeutics, Inc. shareholders approved Amendment to Fifth Amended and Restated Certificate of Incorporation to limit liability of certain officers as permitted by Delaware law at the 2023-06-15 meeting.
  - Proposal: charter amendment
  - Outcome: passed
  - Meeting: 2023-06-15
  source text: The stockholders of the Company approved the amendment to the Company’s Fifth Amended and Restated Certificate of Incorporation to limit the liability of certain officers of the Company as permitted by recent amendments to Delaware law.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662579/000162828023022597/0001628280-23-022597-index.htm
- Shareholder Votes
  C4 Therapeutics, Inc. shareholders approved Election of Class III directors at the 2023-06-15 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-15
  source text: The stockholders of the Company elected each of Andrew J. Hirsch, Utpal Koppikar and Malcom Salter as Class III directors, to hold office until the 2026 annual meeting of stockholders and until their respective successors have been duly elected and qualified or until his or her earlier resignation or removal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662579/000162828023022597/0001628280-23-022597-index.htm
- Shareholder Votes
  C4 Therapeutics, Inc. shareholders approved Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-15 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-15
  source text: The stockholders of the Company ratified the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662579/000162828023022597/0001628280-23-022597-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.